This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Neelapu, S. S. et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. Nat. Med. https://doi.org/10.1038/s41591-022-01731-4 (2022)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Killock, D. CAR T cells show promise in the frontline for high-risk LBCL. Nat Rev Clin Oncol 19, 283 (2022). https://doi.org/10.1038/s41571-022-00628-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-022-00628-y